Moderna, Inc. MRNA
231.35 USD -17.34 (-6.97%)
At closeNov 12, 2026, 7:58 PM EST
230.82 -0.53 -0.23%
After hours · Nov 12, 7:58 PM ET
229.69 Day range 245.37
22.28 52-week range 280.80
- YTD
- +684.50%
- 1 year
- +766.15%
News
barrons.com BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy. BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
marketbeat.com Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook Moderna NASDAQ: MRNA is preparing to seek U.S. approval of its individualized cancer treatment intismeran by year-end, with executives aiming for a 2027 launch alongside partner Merck if regulators…
zacks.com MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock? Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.
fool.com Why Moderna Stock Dropped on Thursday Moderna's revenue guidance for 2026 falls short of analyst targets, meaning a sales miss may be coming. Moderna's earnings might surprise to the upside if its cost-cutting pays off.
barrons.com Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes. The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine.
benzinga.com Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities Moderna raises its 2026 revenue forecast to 15%-25% and accelerates oncology investments, expanding its mRNA platform into new therapies.
benzinga.com Moderna Raises FY26 Sales Growth Guidance To 15%-25% From 10%; On Track To Achieve FY26 Gross Margin Expansion Of ~10 Percentage Points Excluding Litigation Settlement Charge; Expects Annual Cash Costs Of ~$4B-$4.5B Over 2027-2030; Sees Ending 2026 With ~$9B In Total Liquidity, Including Cash, Investments And Undrawn Borrowing Capacity Moderna, Inc. (NASDAQ:MRNA) today outlined the next phase of growth at its 2026 Analyst Day, highlighting how more than a decade of investment in the Company's mRNA platform has enabled the…
benzinga.com Moderna Highlights JAMA Publication Of Real-World Comparative Effectiveness Data For COVID-19 Vaccine Adults Aged 65 Years and Older Real-world analysis of more than 294,000 U.S. Veterans aged 65 and older found mNEXSPIKE was associated with a 35.9% lower risk of medically attended COVID-19 and a 47% lower risk of…
defenseworld.net 71 West Capital Partners Acquires New Holdings in Moderna, Inc. $MRNA 71 West Capital Partners bought a new stake in shares of Moderna, Inc. (NASDAQ: MRNA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The…
fool.com Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy Moderna's revenue came in better than expected last quarter, and the company raised its guidance. Nearly all of its revenue comes from COVID-related products.
zacks.com Can Moderna's First Cancer Therapy Win FDA Approval in 2027? MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.
benzinga.com Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $195 Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $137 to $195.- benzinga.com Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $305 Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $230 to $305.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
zacks.com Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology MRNA raises its 2026 revenue growth outlook after strong Q3 results, lower costs and respiratory vaccine gains, while advancing its oncology pipeline.
fool.com BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. BioNTech and Moderna are working to reduce their dependence on COVID-19 vaccines through expanding pipelines in cancer treatment and other diseases. Moderna's latest quarterly results showed…
fool.com Moderna: 3 Key Takeaways for Long-Term Investors Moderna raised full-year 2026 revenue growth guidance to 15% to 25%. Intismeran reduced the risk of melanoma recurrence or death by 42% in Phase 3.
zacks.com Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell? Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.
seekingalpha.com Moderna, Inc. (MRNA) Q3 2026 Earnings Call Transcript Moderna, Inc. ( MRNA ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock -…
zacks.com MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.
reuters.com GSK, Moderna settle patent dispute over Moderna COVID, RSV shots GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
fool.com Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction Revenue jumped 29% on international COVID vaccine sales tied to long-term government deals. Moderna raised its 2026 revenue growth outlook to 15% to 25%.
benzinga.com Moderna Stuns Wall Street With Surprise Profit, Raises Outlook Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
zacks.com Great Jobs Report. Will It Matter to Market Participants? BLS results were far better than expected: +165K, close to triple the +59K analysts were looking for.
marketbeat.com What Moderna (MRNA) Said on Its Q3 Earnings Call Moderna NASDAQ: MRNA raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international…
247wallst.com Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
schaeffersresearch.com Moderna Stock Pops, Taps Multi-Year High After Earnings Moderna (NASDAQ:MRNA) stock was last seen up 3.9% to trade at $250.95 after reporting third-quarter earnings of $0.38 per share on $1.3 billion in revenue, versus Wall Street estimates of a loss of…- benzinga.com Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
fool.com Moderna Just Gave Investors Yet Another Thing to Cheer About Moderna earned a surprise profit in the third quarter, while analysts expected a loss of more than $1 per share. Management raised its full-year revenue growth outlook to 15% to 25% and cut its R&D…
schaeffersresearch.com Nasdaq Futures Jump as Volatile Week Continues Stock futures are trading mixed as Wall Street digests today's nonfarm payrolls data and yesterday's steep selloff
benzinga.com Moderna Q3 2026 Earnings Call Transcript Moderna (NASDAQ:MRNA) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Moderna (MRNA) Q3 Earnings and Revenues Top Estimates Moderna (MRNA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $1.1 per share. This compares to a loss of $0.51 per share a year ago.
barrons.com Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts. Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.
wsj.com Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.
marketwatch.com Moderna's stock jumps after biotech raises sales outlook The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.
reuters.com Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas Nov 6 (Reuters) - Moderna (MRNA.
cnbc.com Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous…
benzinga.com Moderna Raises FY2026 Sales Guidance from $2.138B to $2.236B-$2.430B vs $2.102B Est Moderna (NASDAQ:MRNA) raises FY2026 sales outlook from $2.138 billion to $2.236 billion-$2.430 billion vs $2.102 billion estimate.
benzinga.com Moderna Q3 EPS $0.38 Beats $(1.26) Estimate, Sales $1.313B Beat $885.051M Estimate Moderna (NASDAQ:MRNA) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $(1.26) by 130.16 percent. This is a 174.51 percent increase over losses of $(0.51)…
benzinga.com Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Moderna, Inc. (NASDAQ:MRNA) will release earnings for its third quarter before the opening bell on Friday, Nov. 6.
benzinga.com Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Moderna reports Q3 earnings Friday, with analysts expecting a $1.25 loss per share and $890M revenue; shares fell 6.6% after vaccine approvals.
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds hit 62% as Wall Street eyes jobs data and a tech rebound.
benzinga.com Moderna Says Health Canada Authorizes mFLUSIVA And mCOFLU For Adults 50 Years Of Age And Older Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®CAMBRIDGE, MA / ACCESS Newswire /…
benzinga.com Enbridge, Moderna On Deck Friday As Demand, Vaccine Pipeline Face Test Enbridge headlines Friday’s reports, with investors weighing whether resilient pipeline utilization can offset a softer revenue comparison. Moderna, Brookfield Asset Management, Humana, Vistra, PPL,…
benzinga.com Moderna's Data From Its Current Phase 1/2 Trial Of mRNA-2808 Selected For Oral Presentation At 68th American Society Of Hematology Annual Meeting Moderna, Inc. (NASDAQ:MRNA) today announced that initial clinical data from its ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of…
benzinga.com Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday U.S. stocks surged, led by Wayfair after strong results; Cricut, Array Technologies, Clear Secure and others also posted double-digit gains.
benzinga.com Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop? Tempus AI, a company that Cathie Wood has invested in, will publish its financial results this week as its volatility continues.
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
benzinga.com Merck One of Top Large-Cap Biopharma Picks-Analyst Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
benzinga.com This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.